Capricor Therapeutics Inc
NASDAQ:CAPR

  • LAST PRICE
    9.1000
  • TODAY'S CHANGE (%)
    3.1300 (52.4288%)
  • Bid / Lots
    8.8400/ 3
  • Ask / Lots
    8.8800/ 2
  • Open / Previous Close
    8.4300 / 5.9700
  • Day Range
    7.4239
    9.2449
  • 52 Week Range
    2.6800
    9.2449
  • Volume
    30,237,566

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
CAPR
Capricor Therapeutics Inc
194.3M
-9.8x
---
CLLS
Cellectis SA
157.7M
-1.1x
---
MDWD
Mediwound Ltd
189.0M
-8.0x
---
ELUT
Elutia Inc
131.1M
-1.2x
---
FENC
Fennec Pharmaceuticals Inc
139.8M
127.0x
---
CRBU
Caribou Biosciences Inc
171.7M
-1.4x
---
As of 2024-09-24

Company Information

Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. The Company leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins and small molecule therapeutics to potentially treat and prevent a diverse array of diseases.

Contact Information

Headquarters
10865 Road to the Cure, Suite 150SAN DIEGO, CA, United States 92121
Phone
858-727-1755
Fax
302-655-5049

Executives

Executive Chairman of the Board
Frank Litvack
President, Chief Executive Officer, Director
Linda Marban
Chief Financial Officer
Anthony Bergmann
Executive Vice President, General Counsel
Karen Krasney
Independent Director
Paul Auwaerter

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$194.3M
Revenue (TTM)
$27.2M
Shares Outstanding
32.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
3.92
EPS
$-0.93
Book Value
$0.73
P/E Ratio
-9.8x
Price/Sales (TTM)
7.2
Price/Cash Flow (TTM)
---
Operating Margin
-110.50%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.